Anti-Inflammatory Treatment of COVID-19 Pneumonia With Tofacitinib Alone or in Combination With Dexamethasone is Safe and Possibly Superior to Dexamethasone as a Single Agent in a Predominantly African American Cohort.

OBJECTIVE: To explore the survival benefit of tofacitinib in addition to dexamethasone in hospitalized patients treated for coronavirus disease 2019 (COVID-19)-related pneumonia. PATIENTS AND METHODS: This is a single-center retrospective observational study. All patients who were hospitalized at Delta Regional Medical Center (a regional hospital in the Mississippi Delta) with a COVID-19 diagnosis and discharged between March 1 and September 30, 2020, are included. The primary outcome was in-hospital mortality in relation to receipt of tofacitinib alone or in addition to dexamethasone (designated as the tofacitinib group), versus dexamethasone alone (designated as the dexamethasone group). RESULTS: Of 269 eligible patients, 138 (51.3%) received tofacitinib uniformly and 131 (48.7%) patients received dexamethasone without tofacitinib. A total of 44 patients expired: 14 (31.8%) in the tofacitinib group and 30 (68.2%) in the dexamethasone group. The proportions of death among the tofacitinib and dexamethasone groups were, respectively, 10.1% and 22.9%. This represents a 70% reduction in odds of dying among the tofacitinib group compared to the dexamethasone group after adjusting for age and clinical parameters captured at hospitalization (adjusted odds ratio: 0.30; 95% CI: 0.12 to 0.76; P=.01). CONCLUSION: The in-patient treatment of COVID-19 pneumonia has rapidly evolved. The addition of dexamethasone has made a relevant improvement on survival. Other immunomodulators have yet to show an impact. Here we present the potential survival benefit of the Janus kinase-signal transducer and activator of transcription inhibitor tofacitinib on COVID-19 pneumonia. We found that adding tofacitinib-based anti-inflammatory therapy to a treatment regimen including dexamethasone in COVID-19 pneumonia seems to have potential benefit of improving survival when compared to dexamethasone alone.

Microvascular obstruction and myocardial function after acute myocardial infarction: assessment by using contrast-enhanced cine MR imaging.

UNLABELLED: This study was approved by the Human Investigation Committee of William Beaumont Hospital, and all patients gave informed consent. The purpose of this study was to prospectively compare contrast material-enhanced cine magnetic resonance (MR) imaging with more-standard MR imaging for the evaluation of microvascular obstruction and myocardial function in 80 patients (56 men, 24 women; mean age, 57 years; range, 29-80 years) with acute myocardial infarction after reperfusion therapy. Findings at contrast-enhanced cine MR imaging agreed with the global and transmural extent of microvascular obstruction at first-pass perfusion (intraclass correlation coefficient [IC] of 0.96 [P < .001] and 0.88 [P < .001], respectively) and inversion-recovery gradient-echo (IC of 0.90 [P < .001] and 0.93 [P < .001], respectively) MR imaging. There was no significant difference between myocardial function parameters before and after contrast material enhancement. Contrast-enhanced cine MR imaging reduced imaging time by 34% (11 of 32 minutes) and improved spatial resolution. SUPPLEMENTAL MATERIAL: radiology.rsnajnls.org/cgi/content/full/240/2/529/DC1